█ INTRODUCTION C ushing's syndrome is a very rare endocrine disorder with a 2-3 per million incidence that results from chronic exposure to hypercortisolism (1). Cushing's disease is caused by excessive secretion of adrenocorticotropic hormone (ACTH) originating from a microadenoma (tumor size <1 cm) in 85-87% of the cases and a macroadenoma (tumor size >1 cm) in 13-15% (13) .
Apoplexy occurs most commonly (>70 % of all cases) in non-functional pituitary macroadenomas with an incidence of 1.6-12.8% (14) and also in growth hormone and prolactin secreting adenomas (9) . It can be seen almost at any age, usually spontaneously but sometimes precipitating condition can also be detected (4) . ACTH secreting adenomas present usually as microadenomas and in these patients apoplexy is rarely seen.
We herein present a patient with Cushing's disease who had pituitary apoplexy after the dexamethasone suppression test.
Pituitary apoplexy is a medical condition that needs urgent diagnosis and treatment. It may occur spontaneously or may be precipitated by a variety of reasons including dynamic endocrine tests. Although pituitary apoplexy is usually seen in nonfunctional pituitary adenoma, it can also be seen in ACTH secreting macroadenomas. ACTH secreting adenomas present usually as microadenomas and in these patients apoplexy is rarely seen. In this paper we present a 30-year-old male patient with a history of Cushing's disease who suffered from pituitary apoplexy after the 1 mg dexamethasone suppression test. He underwent endoscopic endonasal transsphenoidal surgery and his symptoms and signs were significantly improved.
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Pituitary apoplexy is a clinical syndrome secondary to rapid expansion of the content of the sella and extension to suprasellar region, cavernous sinus and sphenoid sinus due to bleeding, ischemic or mixed episode (ischemic and hemorrhagic) taking place within the pituitary adenoma (16) . Risk factors for apoplexy include trauma, increased intracranial pressure, using anticoagulants, bromocriptine treatment, diabetic ketoacidosis, conventional angiography, radiotherapy In a retrospective study from Romania, out of 98 patients with pituitary apoplexy (F:M=1.7:1), 64 (65.3%) patients had nonfunctional pituitary tumor, 24 (24.5%) had prolactinoma, 7 (7.1%) had growth hormone-secreting tumor and 3 (3.1%) had ACTH-secreting tumor (16) . Generally, frequency of apoplexy is low in ACTH-secreting pituitary adenomas (3). (12) . It has been suggested that glucocorticoids may increase catecholamines and these may lead to vasospasm and cause apoplexy. Tutanç et al. reported pituitary apoplexy occurred during levothyroxine treatment in a case of congenital hypothyroidism (14) .
A B
The exact mechanism of pituitary apoplexy is not clear. Nonetheless, several hypotheses have been put forward. These include rapid expansion of a tumor outgrowing its own blood supply (which leads to ischemic necrosis), growth of a tumor leading to compression of the pituitary portal blood supply against the diaphragma sella, and intrinsic vasculopathy or fragility of the blood vessels supporting a pituitary tumor. The clinicopathological consequences of pituitary apoplexy are caused by a rapid increase in size of the contents of the pituitary fossa and consequent elevation of intrasellar pressure (10).
ACTH-secreting macroadenomas are rare and apoplexy due to them has been reported very rarely (15) . Rate of remissions in cases of ACTH-secreting macroadenomas without apoplexy is low; however, it is high in cases with apoplexy (11) . Longterm follow-up is necessary in cases with apoplexy even in the presence of remission. Relapses have been reported even after seven years in cases of apoplexy (12) . The start of the spontaneous regression of pituitary adenomas following apoplexy has not been clearly defined nor has the time it takes for complete resolution been clearly defined (2).
█ CONCLUSION
While apoplexy is reported after endocrine stimulation tests, in our case the precipitating factor was not a stimulation but a suppression test. Association between suppression tests and apoplexy is not clearly defined, and this is the first report of pituitary apoplexy that developed during a suppression test. Physicians should be aware of this fact and consider pituitary apoplexy after suppression tests as well.
